# A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

> **NCT02963831** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 67 (actual)

## Conditions studied

- Colorectal Cancer
- Ovarian Cancer
- Appendiceal Cancer

## Interventions

- **BIOLOGICAL:** ONCOS-102
- **DRUG:** Durvalumab
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02963831
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-07
- **Primary completion:** 2022-06-25
- **Final completion:** 2022-06-25
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2022-12-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963831, "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02963831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*